{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:39:37Z","timestamp":1793137177507,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109385","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:38:20Z","timestamp":1774658300000},"page":"109385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial"],"prefix":"10.1016","volume":"216","author":[{"given":"Fabrice","family":"Barlesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-6730","authenticated-orcid":false,"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-4165","authenticated-orcid":false,"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-9843","authenticated-orcid":false,"given":"Rafal","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Migliorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilze","family":"Bara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Ngiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Petric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109385_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2026.109385_b0010","unstructured":"Ferlay JE ML, F. Laversanne, M. Colombet, M. Mery, L. Pi\u00f1eros, M. Znaor, A. Soerjomataram, I. Bray, F. Global Cancer Observatory: cancer today. Accessed January 21, 2025. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf; 2024."},{"key":"10.1016\/j.lungcan.2026.109385_b0015","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2217\/fon-2021-1417","article-title":"Real-world treatment patterns in resectable (stages I-III) non-small-cell lung cancer: a systematic literature review","volume":"18","author":"Waser","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2026.109385_b0020","unstructured":"NCCN, Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.7.2024\u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved, Accessed Feb 19, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. 2024; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.lungcan.2026.109385_b0025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109385_b0030","first-page":"242","article-title":"Recurrence after surgery in patients with NSCLC","volume":"3","author":"Uramoto","year":"2014","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109385_b0035","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109385_b0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21037\/tlcr-22-631","article-title":"Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review","volume":"12","author":"Chen","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109385_b0045","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109385_b0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2018.05.020","article-title":"Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer","volume":"122","author":"Chaft","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109385_b0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12916-021-02207-x","article-title":"Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study","volume":"20","author":"Zou","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.lungcan.2026.109385_b0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109385_b0065","unstructured":"European Medicines Agency, ALECENSA\u00ae (alectinib) summary of product characteristics, Accessed Jan 21, 2025, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alecensa-epar-product-information_en.pdf; 2024."},{"key":"10.1016\/j.lungcan.2026.109385_b0070","unstructured":"US Food and Drug Administration, ALECENSA\u00ae (alectinib) highlights of prescribing information, Accessed Jan 22, 2025, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208434s015lbl.pdf; 2024."},{"key":"10.1016\/j.lungcan.2026.109385_b0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109385_b0080","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109385_b0085","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109385_b0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109385_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100612","article-title":"Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib","volume":"7","author":"Dziadziuszko","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109385_b0100","unstructured":"Roche, European commission approves Roche\u2019s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer, Accessed Feb 5, 2025, https:\/\/www.roche.com\/media\/releases\/med-cor-2024-06-10#:\u223c:text=Alecensa%20was%20approved%20by%20the,as%20a%20monotherapy%20for%20adjuvant; 2024."},{"key":"10.1016\/j.lungcan.2026.109385_b0105","doi-asserted-by":"crossref","unstructured":"M.B. Amin, F.L. Greene, S.B. Edge, et al., The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging, CA Cancer J Clin, 2017;67:93-99, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28094848.","DOI":"10.3322\/caac.21388"},{"key":"10.1016\/j.lungcan.2026.109385_b0110","doi-asserted-by":"crossref","unstructured":"F.C. Detterbeck, The eighth edition TNM stage classification for lung cancer: what does it mean on main street? J. Thorac. Cardiovasc. Surg. 2018;155:356-359.","DOI":"10.1016\/j.jtcvs.2017.08.138"},{"key":"10.1016\/j.lungcan.2026.109385_b0115","doi-asserted-by":"crossref","unstructured":"J. Huang, R.U. Osarogiagbon, D.J. Giroux, et al., The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer, J. Thorac. Oncol. 2024;19:766-785.","DOI":"10.1016\/j.jtho.2023.10.012"},{"key":"10.1016\/j.lungcan.2026.109385_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1510\/icvts.2011.268979","article-title":"In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior?","volume":"13","author":"Hughes","year":"2011","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109385_b0125","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.21037\/jtd-21-854","article-title":"Positive nodal status is still a risk factor for long-term survivors of non-small cell lung cancer 5 years after complete resection","volume":"13","author":"Yang","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109385_b0130","doi-asserted-by":"crossref","unstructured":"R. Rami-Porta, V. Bolejack, J. Crowley, et al., The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer, J. Thorac. Oncol. 2015;10:990-1003.","DOI":"10.1097\/JTO.0000000000000559"},{"key":"10.1016\/j.lungcan.2026.109385_b0135","unstructured":"Roche, A study to see how well and how safely different treatments work in a group of participants with non-small cell lung cancer (NSCLC) (HORIZON 2), Accessed Feb 5, 2025, https:\/\/clinicaltrials.gov\/study\/NCT06624059; 2025."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:23:02Z","timestamp":1782663782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S0169500226004460"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109385","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109385"}}